For instance, in the SURPASS-4 trial, where tirzepatide was compared with insulin glargine in patients with T2DM and a high cardiovascular risk, 15 mg of tirzepatide reduced the levels of TC, LDL-C, and TGs by 5.6%, 7.9%, and 22.5%, respectively, and increased the levels of HDL-C by 10.8%.5 In the SURPASS-5 trial, where tirzepatide was added to basal insulin treatment, tirzepatide also showed favorable effects on lipid profile parameters compared with placebo in patients with T2DM.6 Specifically, tirzepatide reduced the levels of TC, LDL-C, and TGs by 12.9%, 15.5%, and 24.9%, respectively, and increased the levels of HDL-C by 0.9%.6 In both trials, the effects of tirzepatide on lipid profile were dose-dependent, with greater improvements observed at higher doses and these improvements were sustained over the duration of the trials.5, 6 Table 1 summarizes the main findings of the SURPASS programs regarding the ability of tirzepatide to improve atherogenic dyslipidemia
Your primary care provider or endocrinologist should review your baseline TSH and free T4 levels before starting GLP-1 therapy, and periodic monitoring during treatment ensures any levothyroxine dose adjustments are made promptly
However, as oxidative stress increases, the permeability of this barrier increases, and free radicals can cross the barrier
Persistent breeding-induced endometritis in mares a multifaceted challenge: from clinical aspects to immunopathogenesis and pathobiology
Separate clinical trials suggest weight-loss results are broadly in a similar range, but the two formulations are not directly interchangeable and should not be compared as if they were studied head to head." How Does Wegovy Tablet Compare To Other Weight Loss Treatments
doi: 10.1542/peds.114.2.e213
-(1).png)
